A possible structural determinant of selectivity of boldine and derivatives for the α1A-adrenoceptor subtype
Author
dc.contributor.author
Madrero, Y.
Author
dc.contributor.author
Elorriaga, M.
Author
dc.contributor.author
Martinez, S.
Author
dc.contributor.author
Noguera, M. A.
Author
dc.contributor.author
Cassels Niven, Bruce
Author
dc.contributor.author
D'Ocon, P.
Author
dc.contributor.author
Ivorra, M. D.
Admission date
dc.date.accessioned
2018-12-20T14:32:15Z
Available date
dc.date.available
2018-12-20T14:32:15Z
Publication date
dc.date.issued
1996
Cita de ítem
dc.identifier.citation
British Journal of Pharmacology, Volumen 119, Issue 8, 2018, Pages 1563-1568
Identifier
dc.identifier.issn
00071188
Identifier
dc.identifier.other
10.1111/j.1476-5381.1996.tb16073.x
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/156323
Abstract
dc.description.abstract
1 The selectivity of action of boldine and the related aporphine alkaloids, predicentrine (9-O-methylboldine) and glaucine (2,9-O-dimethylboldine) on α1-adrenoceptor subtypes was studied by examining [3H]-prazosin competition binding in rat cerebral cortex. WB 4101 and benoxathian were used as selective α1A-adrenoceptor antagonists. 2 In the competition experiments [3H]-prazosin (0.2 nM) binding was inhibited by WB 4101 and benoxathian. The inhibition curves displayed shallow slopes which could be subdivided into high and low affinity components (pKi=9.92 and 8.29 for WB 4101, 9.35 and 7.94 for benoxathian). The two antagonists recognized approximately 37% of the sites with high affinity from among the total [3H]-prazosin specific binding sites. 3 Boldine, predicentrine and glaucine also competed for [3H]-prazosin (0.2 nM) binding with shallow and biphasic curves recognizing 30-40% of the sites with high affinity. Drug affinities (pKi) at the high and low affinity sites were, 8.31 and